Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 9/20 | 0.69 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.69 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132459 | 0.91 | GNAI3 (0.61) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL12991627 | 0.86 | GAA (0.59) | GNAI3GNAI1GNAO1L3MBTL1KMT2A | |
| SCHEMBL10537382 | 0.85 | GNAI3 (0.67) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL10757141 | 0.85 | GNAI3 (0.67) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL5606242 | 0.85 | GNAI3 (0.67) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL10535769 | 0.85 | GNAI3 (0.67) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL9427599 | 0.85 | GNAI3 (0.67) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL10535735 | 0.85 | GNAI3 (0.67) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL27663325 | 0.84 | GNAI3 (0.65) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL9428505 | 0.83 | GNAI3 (0.64) | GNAI3GNAI1GNAO1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009077844-A2 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | QUONOVA LLC (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | PGLS, TFPI, Q6ZSR9 | GNAI3 49/4885GNAI1 28/4885GNAO1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.